| Identification | Back Directory | [Name]
Motapizone | [CAS]
90697-57-7 | [Synonyms]
Motapizone
4,5-Dihydro-6-[4-(1H-imidazol-1-yl)-2-thienyl]-5-methylpyridazin-3(2H)-one
3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(1H-imidazol-1-yl)-2-thienyl]-5-methyl- | [Molecular Formula]
C12H12N4OS | [MDL Number]
MFCD00865861 | [MOL File]
90697-57-7.mol | [Molecular Weight]
260.31 |
| Hazard Information | Back Directory | [Uses]
Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP[1][2]. | [IC 50]
PDE3 | [References]
[1] Milara J, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011 Apr;41(4):535-46. DOI:10.1111/j.1365-2222.2011.03715.x
[2] Borbe HO, et al. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl. 1986;20:249-57. PMID:3028104 |
|
|